Pharmaceutical composition

A composition and drug technology, applied in the field of medicine, can solve problems such as unreported applications, and achieve the effects of reducing cerebral infarction size, reducing neurological function scores, and improving vitality

Active Publication Date: 2018-09-14
CHINA PHARM UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] There is no report in the prior art about the pharmaceutical composition of lactone components, f

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition
  • Pharmaceutical composition
  • Pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Embodiment 1: pharmaceutical composition of the present invention (7+1 composition, weight ratio middle value)

[0051] Made by uniformly mixing the ingredients in Table 1:

[0052] Table 1 Pharmaceutical composition composition and content

[0053]

[0054] In this embodiment, lactone components account for 37.80% of the total weight of the composition; flavonoid components account for 61.99% of the total weight of the composition; organic acid components account for 0.21% of the total weight of the composition. Quercetin, kaempferol, epigallocatechin gallate, myricetin, isorhamnetin-3-O-rutinoside, and kaempferol-7-O-p-coumaroyl-3-O-rhamnoside The weight ratio of sugar-(1,2)-glucoside is 0.110:0.039:0.030:0.040:2.827:2.163.

Embodiment 2

[0055] Embodiment 2: pharmaceutical composition of the present invention (12+1 composition, weight ratio middle value)

[0056] Made by uniformly mixing the ingredients in Table 2:

[0057] Table 2 Pharmaceutical composition composition and content

[0058]

[0059] In this embodiment, lactone components account for 22.81% of the total weight of the composition; flavonoid components account for 77.09% of the total weight of the composition; organic acid components account for 0.10% of the total weight of the composition. The weight ratio of bilobalide and ginkgolide B is 3.176:1.084. Quercetin, kaempferol, epigallocatechin gallate, myricetin, isorhamnetin-3-O-rutinoside, kaempferol-7-O-p-coumaroyl-3-O-rhamnoside Sugar-(1,2)-glucoside, isorhamnetin, quercetin-3-O-rutinoside, quercetin-3-O-2"-(6"-p-coumaroyl)-glucose The weight ratio of the base-rhamnoside and the kaempferol-3-O-rutinoside is 0.110:0.039:0.030:0.040:2.827:2.163:0.054:3.918:2.259:2.958.

Embodiment 3

[0060] Embodiment 3: pharmaceutical composition of the present invention (17+1 composition, weight ratio middle value)

[0061] Made by uniformly mixing the ingredients in Table 3:

[0062] Table 3 pharmaceutical composition composition and content

[0063]

[0064]

[0065] In this embodiment, lactone components account for 28.67% of the total weight of the composition; flavonoid components account for 64.88% of the total weight of the composition; organic acid components account for 6.45% of the total weight of the composition. The weight ratio of bilobalide, ginkgolide B, ginkgolide A and ginkgolide C is 3.176:1.084:2.232:1.003. Quercetin, kaempferol, epigallocatechin gallate, myricetin, isorhamnetin-3-O-rutinoside, kaempferol-7-O-p-coumaroyl-3-O-rhamnoside Sugar-(1,2)-glucoside, isorhamnetin, quercetin-3-O-rutinoside, quercetin-3-O-2"-(6"-p-coumaroyl)-glucose of kaempferol-3-O-rutinoside, kaempferol-3-O-rutinoside, kaempferol-3-O-2"-(6"-p-coumaroyl)-glucosyl-rhamn...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition which is specially the pharmaceutical composition for treating ischemic cerebral stroke. The pharmaceutical composition is based on total weight ofthe composition and comprises 18.1%-50.9% of lactone constituents, 48.8%-81.8% of flavonoid constituents and 0.07%-6.83% of organic acid constituents. The pharmaceutical composition including the lactone constituents, the flavonoid constituents and the organic acid constituents and application thereof in the treatment of the ischemic cerebral stroke are not reported in the prior art. The pharmaceutical composition of the invention can effectively reduce cerebral infarction area of a mouse of a cerebral ischemia reperfusion model and reduce a neurological function score of the mouse, can significantly improve the activity of neuron cells of an oxygen-glucose deprivation/hypoxia-reoxygenation neuron cell damage model, has a substantial protection effect on an inflammation of LPS induction microglia, is safe and effective, and can be prepared as a drug for preventing or treating the ischemic cerebral stroke.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating ischemic stroke. Background technique [0002] Ischemic stroke, also known as "stroke", is an acute cerebrovascular disease. It is a group of diseases that cause brain tissue damage due to sudden blockage of blood vessels in the brain that prevents blood from flowing into the brain. The incidence of ischemic stroke accounts for 60% to 70% of the total number of strokes. It has the characteristics of high morbidity, high mortality and high disability rate, but there has been a lack of effective treatment methods. [0003] Thrombolytic therapy is currently recognized as the most effective treatment for stroke, but it has strict time window requirements (intravenous thrombolysis is limited to 4.5 hours, and arterial thrombolysis can be extended appropriately). Patients with existing hypertension, diabetes,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61K31/365A61K31/353A61K31/352A61K31/216A61K31/192A61P9/10A61P25/00C07H17/07C07H1/06
CPCA61K31/192A61K31/216A61K31/352A61K31/353A61K31/365A61K31/7048C07H1/06C07H17/07A61K2300/00
Inventor 李萍杨华刘新光
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap